Yukio Sekiguchi

Yukio Sekiguchi

Auto-generated profile, based on publicly available information

Yukio Sekiguchi

Cardiovascular Division, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
YNYoshihisa Naruse
Yoshihisa Naruse
YSYukio Sekiguchi
Yukio Sekiguchi
ANAkihiko Nogami
Akihiko Nogami
HOHiroyuki Okada
Hiroyuki Okada
YYYasuteru Yamauchi
Yasuteru Yamauchi
KAKazutaka Aonuma
Kazutaka Aonuma
Background—Fatal arrhythmia is commonly observed in cardiac sarcoidosis, but clinical effects of a systematic treatment approach are still uncertain. This study sought to describe both clinical and electrophysiological characteristics and outcomes of systematic treatment approach to ventricular tachycardia (VT) associated with cardiac sarcoidosis. Methods and Results—We enrolled 37 consecutive patients (11 men; age, 56±11 years) with a diagnosis of sustained VT associated with cardiac sarcoidosis. Clinical effects of a systematic treatment approach including medical therapy (both steroid and antiarrhythmic agents), in association with radiofrequency catheter ablation, were evaluated. All patients received antiarrhythmic agents, and 34 received steroid therapy. During a 39-month follow-up, 23 (62%) patients were free from any VT episodes with medical therapy. Multivariable Cox regression analyses revealed that the absence of gallium-67 myocardial uptake was an independent predictor for VT recurrence (hazar...

14 July 2016 in Modern Rheumatology
Verified
Journal Article
Closed access
NTNaruhiko Takasawa
Naruhiko Takasawa
YSYukio Sekiguchi
Yukio Sekiguchi
TTTsuneyuki Takahashi
Tsuneyuki Takahashi
AMAkira Muryoi
Akira Muryoi
JSJo Satoh
Jo Satoh
TSTakeshi Sasaki
Takeshi Sasaki
We report a case of a 46-year-old woman with fever, pleural effusion, massive ascites, severe edema, hepatosplenomegaly, elevation of serum creatinine level, proteinuria, and severe thrombocytopenia. Her clinical features were compatible with TAFRO syndrome proposed as a variant of multicentric Castleman’s disease, that is occasionally associated with poor prognosis. Treatment with corticosteroid improved her symptoms partially. However, thrombocytopenia, ascites, and edema persisted. The use of cyclosporine A successfully improved her condition, resulting in remission.

1 August 2015 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
KDKosuke Doki
Kosuke Doki
YSYukio Sekiguchi
Yukio Sekiguchi
KKKeisuke Kuga
Keisuke Kuga
KAKazutaka Aonuma
Kazutaka Aonuma
MHMasato Homma
Masato Homma

1 September 2008 in Journal of Nuclear Cardiology
Verified
Journal Article
Closed access
ASAkira Sato
Akira Sato
KAKazutaka Aonuma
Kazutaka Aonuma
TNToshihiro Nozato
Toshihiro Nozato
YSYukio Sekiguchi
Yukio Sekiguchi
OOOsamu Okazaki
Osamu Okazaki
MHMichiaki Hiroe
Michiaki Hiroe

1 September 2016 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Open access
KMKeita Masuda
Keita Masuda
ANAkihiko Nogami
Akihiko Nogami
KKKenji Kuroki
Kenji Kuroki
MIMiyako Igarashi
Miyako Igarashi
YSYukio Sekiguchi
Yukio Sekiguchi
KAKazutaka Aonuma
Kazutaka Aonuma
Background—: Catheter ablation is an effective therapy for ventricular fibrillation (VF) arising from the Purkinje system in ischemic heart disease. However, some patients experience newly emergent monomorphic ventricular tachycardia (VT) after the ablation of VF. We evaluated the prevalence and mechanism of monomorphic VT after VF ablation. Methods and Results—: Twenty-one consecutive patients with primary VF because of ischemic heart disease who underwent catheter ablation were retrospectively analyzed. Twenty of 21 patients were in electrical storm. Ventricular premature contractions triggering VF arose from the left Purkinje system and were targeted for ablation. Before the ablation, 14 of 21 patients had only VF, and the other 7 had VF and concomitant monomorphic VT. Four of the 14 patients with only VF (29%) exhibited newly emergent monomorphic VT after VF ablation. Three of these patients had Purkinje-related VTs, which were successfully eliminated by the ablation of a Purkinje network located in the same low-voltage area as the site of prior successful VF ablation. During a median follow-up of 28 months (interquartile range, 16–68 months), VF recurred in 6 of 21 patients (29%); however, there were neither electrical storms nor monomorphic VT, and all recurring arrhythmias were controlled by medical therapy alone. Conclusions—: Over one fifth of patients with primary ischemic VF experienced newly emergent Purkinje-related monomorphic VT after VF ablation. The circuit of the monomorphic VT associated with the Purkinje network was located in the same low-voltage area as the Purkinje tissue that triggered VF and could be suppressed by additional ablation.

21 April 2016 in Modern Rheumatology
Verified
Journal Article
Open access
PDF file
YHYasuhiko Hirabayashi
Yasuhiko Hirabayashi
YMYasuhiko Munakata
Yasuhiko Munakata
MMMasayuki Miyata
Masayuki Miyata
YUYukitomo Urata
Yukitomo Urata
KSKoichi Saito
Koichi Saito
FGfor the Michinoku Tocilizumab Study Group
for the Michinoku Tocilizumab Study Group
Objective. To evaluate the clinical and structural efficacy of tocilizumab (TCZ) during its long-term administration in patients with rheumatoid arthritis (RA). Methods. In total, 693 patients with RA who started TCZ therapy were followed for 3 years. Clinical efficacy was evaluated by DAS28-ESR and Boolean remission rates in 544 patients. Joint damage was assessed by calculating the modified total Sharp score (mTSS) in 50 patients. Results. When the reason for discontinuation was limited to inadequate response or adverse events, the 1-, 2-, and 3-year continuation rates were 84.0%, 76.8%, and 72.2%, respectively. The mean DAS28-ESR was initially 5.1 and decreased to 2.5 at 6 months and to 2.2 at 36 months. The Boolean remission rate was initially 0.9% and increased to 21.7% at 6 months and to 32.2% at 36 months. The structural remission rates (ΔmTSS/year ≤0.5) were 68.8%, 78.6%, and 88.9% within the first, second, and third years, respectively. The structural remission rate at 3 years (ΔmTSS ≤1.5) was 66.0%, and earlier achievement of swollen joint count (SJC) of 1 or less resulted in better outcomes. Conclusions. TCZ was highly efficacious, and bone destruction was strongly prevented. SJC was an easy-to-use indicator of joint destruction.